DNA ploidy combined with tumor stroma as a biomarker for predicting the prognosis of stage II colorectal cancer patients and identifying candidates for chemotherapy
While ploidy and stroma alone do not possess predictive power regarding survival outcomes for stage II colorectal cancer patients, those receiving chemotherapy within the PS-H group demonstrated enhanced survival rates. Therefore, combining assessments of ploidy and stroma may serve as an adjunctive tool in clinical decision-making processes to guide chemotherapy treatment strategies for patients diagnosed with stage II colorectal cancer.
Authors
- Yunshan Zhao (ORCID: https://orcid.org/0000-0002-9412-9512)
- Xiaohui Du (ORCID: https://orcid.org/0000-0002-8713-1358)
- Xudong Zhao (ORCID: https://orcid.org/0000-0002-1864-4686)
- Shaoyou Xia (ORCID: https://orcid.org/0000-0003-3263-6022)
- Fei Wang (ORCID: https://orcid.org/0000-0003-2930-8941)
- Lijun Mao (ORCID: https://orcid.org/0000-0002-8611-6025)
- Zhigang Song (ORCID: https://orcid.org/0000-0003-1357-089X)
- Zufeng He
Institutions
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1186/s12957-025-03693-6
- Citations
- 1
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- General Hospital of People’s Liberation Army